Platform &
pipeline
Our approach: Reprogramming autophagy
Casma is developing a new way to do targeted degradation. Many important disease targets go beyond the capacity of the ubiquitin-proteasome pathway. The PHLYT™ technology reprograms autophagy to generate autophagosomes around these disease targets resulting in degradation. This is Degradation 2.0.